OGEN (Oragenics) Issuance of Debt: $0.23 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OGEN Oragenics Inc OGEN
30 GF Score
Price $0.56
! 1 Warning Sign
View Full Analysis

What is Oragenics Issuance of Debt?

Oragenics OGEN -1.03% 30 Issuance of Debt is $0.23 Mil as of Mar. 2026. GuruFocus rates OGEN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Oragenics's Issuance of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Oragenics's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.23 Mil.

Oragenics Issuance of Debt Related Terms

Oragenics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Oragenics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oragenics Issuance of Debt Chart

Oragenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.46

Oragenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 0.00 0.40 -0.17 0.00
OGEN
30GF Score
Oragenics Inc OGEN
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oragenics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.23 Mil mean?
Oragenics (OGEN) has a Issuance of Debt of $0.23 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Oragenics and its competitors.
Is Oragenics' Issuance of Debt too high?
Oragenics' current Issuance of Debt is $0.23 Mil. Overall, Oragenics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Oragenics' Issuance of Debt compare to ITRMF and CASIF?
Oragenics' Issuance of Debt of $0.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Oragenics and its competitors. Oragenics's current Issuance of Debt is $0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oragenics stock overvalued right now?
Oragenics (OGEN) has a current Issuance of Debt of $0.23 Mil. The current Issuance of Debt is $0.23 Mil. Oragenics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Oragenics (OGEN), the current Issuance of Debt is $0.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oragenics Business Description

Address 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL, USA, 34202
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score

Get the complete analysis for OGEN

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price